RESUMEN
BACKGROUND: Autoantibodies against interleukin-12 (anti-interleukin-12) are often identified in patients with thymoma, but opportunistic infections develop in only some of these patients. Interleukin-12 (with subunits p40 and p35) shares a common subunit with interleukin-23 (subunits p40 and p19). In a patient with disseminated Burkholderia gladioli infection, the identification of both anti-interleukin-23 and anti-interleukin-12 prompted further investigation. METHODS: Among the patients (most of whom had thymoma) who were known to have anti-interleukin-12, we screened for autoantibodies against interleukin-23 (anti-interleukin-23). To validate the potential role of anti-interleukin-23 with respect to opportunistic infection, we tested a second cohort of patients with thymoma as well as patients without either thymoma or known anti-interleukin-12 who had unusual infections. RESULTS: Among 30 patients with anti-interleukin-12 who had severe mycobacterial, bacterial, or fungal infections, 15 (50%) also had autoantibodies that neutralized interleukin-23. The potency of such neutralization was correlated with the severity of these infections. The neutralizing activity of anti-interleukin-12 alone was not associated with infection. In the validation cohort of 91 patients with thymoma, the presence of anti-interleukin-23 was associated with infection status in 74 patients (81%). Overall, neutralizing anti-interleukin-23 was detected in 30 of 116 patients (26%) with thymoma and in 30 of 36 patients (83%) with disseminated, cerebral, or pulmonary infections. Anti-interleukin-23 was present in 6 of 32 patients (19%) with severe intracellular infections and in 2 of 16 patients (12%) with unusual intracranial infections, including Cladophialophora bantiana and Mycobacterium avium complex. CONCLUSIONS: Among patients with a variety of mycobacterial, bacterial, or fungal infections, the presence of neutralizing anti-interleukin-23 was associated with severe, persistent opportunistic infections. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
Asunto(s)
Autoanticuerpos , Síndromes de Inmunodeficiencia , Interleucina-23 , Infecciones Oportunistas , Adulto , Humanos , Autoanticuerpos/inmunología , Síndromes de Inmunodeficiencia/inmunología , Interleucina-12/antagonistas & inhibidores , Interleucina-12/inmunología , Interleucina-23/antagonistas & inhibidores , Interleucina-23/inmunología , Micosis/inmunología , Infecciones Oportunistas/inmunología , Timoma/inmunología , Neoplasias del Timo/inmunología , Anticuerpos Neutralizantes/inmunología , Infecciones Bacterianas/inmunologíaRESUMEN
Ataxia-telangiectasia (A-T) is a rare disorder caused by genetic defects of A-T mutated (ATM) kinase, a key regulator of stress response, and characterized by neurodegeneration, immunodeficiency, and high incidence of cancer. Here we investigated NK cells in a mouse model of A-T (Atm-/-) showing that they are strongly impaired at killing tumor cells due to a block of early signaling events. On the other hand, in Atm-/- littermates with thymic lymphoma NK cell cytotoxicity is enhanced as compared with ATM-proficient mice, possibly via tumor-produced TNF-α. Results also suggest that expansion of exhausted NKG2D+ NK cells in Atm-/- mice is driven by low-level expression of stress-inducible NKG2D ligands, whereas development of thymoma expressing the high-affinity MULT1 ligand is associated with NKG2D down-regulation on NK cells. These results expand our understanding of immunodeficiency in A-T and encourage exploring NK cell biology in A-T patients in the attempt to identify cancer predictive biomarkers and novel therapeutic targets.
Asunto(s)
Proteínas de la Ataxia Telangiectasia Mutada , Células Asesinas Naturales , Subfamilia K de Receptores Similares a Lectina de Células NK , Animales , Células Asesinas Naturales/inmunología , Proteínas de la Ataxia Telangiectasia Mutada/genética , Proteínas de la Ataxia Telangiectasia Mutada/metabolismo , Subfamilia K de Receptores Similares a Lectina de Células NK/genética , Subfamilia K de Receptores Similares a Lectina de Células NK/metabolismo , Ratones , Ataxia Telangiectasia/genética , Ataxia Telangiectasia/inmunología , Ratones Noqueados , Ratones Endogámicos C57BL , Timoma/inmunología , Timoma/genética , Factor de Necrosis Tumoral alfa/metabolismo , Factor de Necrosis Tumoral alfa/inmunología , Citotoxicidad Inmunológica , Neoplasias del Timo/inmunología , Neoplasias del Timo/genética , Transducción de Señal , Proteínas de la Membrana , Antígenos de Histocompatibilidad Clase IRESUMEN
BACKGROUND: Thymoma presents with several autoimmune manifestations and is associated with secondary autoimmune regulator (AIRE) deficiency. Pneumonitis has recently been described as an autoimmune manifestation associated with thymoma presenting with similar clinical, radiographic, histological, and autoantibody features as seen in patients with inherited AIRE deficiency who suffer from Autoimmune PolyEndocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) syndrome. OBJECTIVES: To treat two patients with biopsy-proven thymoma-associated pneumonitis with lymphocyte-directed immunomodulation. METHODS: Two patients with thymoma were enrolled on IRB-approved protocols at the NIH Clinical Center. We performed history and physical examination; laboratory, radiographic, histologic and pulmonary function evaluations; and measurement of the lung-directed autoantibodies KCNRG and BPIFB1 prior to and at 1- and 6-months following initiation of lymphocyte-directed immunomodulation with azathioprine with or without rituximab. RESULTS: Combination T- and B-lymphocyte-directed immunomodulation resulted in improvement of clinical, functional, and radiographic parameters at 6-month follow-up evaluations in both patients with sustained remission up to 12-36 months following treatment initiation. CONCLUSION: Lymphocyte-directed immunomodulation remitted autoimmune pneumonitis in two patients with thymoma.
Asunto(s)
Inmunomodulación , Timoma , Humanos , Timoma/inmunología , Timoma/complicaciones , Timoma/diagnóstico , Femenino , Masculino , Rituximab/uso terapéutico , Autoanticuerpos/inmunología , Persona de Mediana Edad , Neoplasias del Timo/inmunología , Neoplasias del Timo/complicaciones , Neoplasias del Timo/diagnóstico , Neumonía/etiología , Neumonía/inmunología , Neumonía/diagnóstico , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/etiología , Adulto , Azatioprina/uso terapéutico , Linfocitos B/inmunología , Resultado del Tratamiento , Linfocitos T/inmunologíaRESUMEN
Myasthenia gravis (MG) is an immune-mediated disease frequently associated with thymic changes. Increased T helper 17 (Th17) cell activity and dysfunctional regulatory T (Treg) cells have been demonstrated in subgroups of MG. On the other hand, hypoxia-inducible factor 1 (HIF-1) has been shown to regulate the Th17/Treg balance by inducing Th17 differentiation while attenuating Treg development. To identify the underlying mechanisms of different thymic pathologies in MG development, we evaluated thymic samples from thymoma-associated myasthenia gravis (TAMG), MG with hyperplasia (TFH-MG) and thymoma without MG (TOMA) patients. Differential gene expression analysis revealed that TAMG and TFH-MG cells are associated with different functional pathways. A higher RORC/FOXP3 ratio provided evidence for Th17/Treg imbalance in TAMG potentially related to increased HIF1A. The hypoxic microenvironment in thymoma may be a driver of TAMG by increasing HIF1A. These findings may lead to new therapeutic approaches targeting HIF1A in the development of TAMG.
Asunto(s)
Subunidad alfa del Factor 1 Inducible por Hipoxia , Miastenia Gravis , Células Th17 , Timoma , Femenino , Humanos , Masculino , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Miastenia Gravis/genética , Miastenia Gravis/inmunología , Miastenia Gravis/patología , Linfocitos T Reguladores/metabolismo , Linfocitos T Reguladores/inmunología , Células Th17/metabolismo , Células Th17/inmunología , Timoma/complicaciones , Timoma/genética , Timoma/inmunología , Timo/patología , Neoplasias del Timo/complicaciones , Neoplasias del Timo/genéticaAsunto(s)
Timoma , Neoplasias del Timo , Humanos , Timoma/inmunología , Timoma/complicaciones , Neoplasias del Timo/inmunología , Neoplasias del Timo/complicaciones , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/etiología , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/etiología , AutoinmunidadRESUMEN
Myasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it is dependent on T cells and characterized by the presence of autoantibodies targeting proteins located on the postsynaptic surface of skeletal muscle, known as the neuromuscular junction. Patients with MG exhibit a spectrum of weakness, ranging from limited ocular muscle involvement to life-threatening respiratory failure. Recent decades have witnessed substantial progress in understanding the underlying pathophysiology, leading to the delineation of distinct subcategories within MG, including MG linked to AChR or MuSK antibodies as well as age-based distinction, thymoma-associated, and immune checkpoint inhibitor-induced MG. This heightened understanding has paved the way for the development of more precise and targeted therapeutic interventions. Notably, the FDA has recently approved therapeutic inhibitors of complement and the IgG receptor FcRn, a testament to our improved comprehension of autoantibody effector mechanisms in MG. In this Review, we delve into the various subgroups of MG, stratified by age, autoantibody type, and histology of the thymus with neoplasms. Furthermore, we explore both current and potential emerging therapeutic strategies, shedding light on the evolving landscape of MG treatment.
Asunto(s)
Autoanticuerpos , Miastenia Gravis , Miastenia Gravis/inmunología , Miastenia Gravis/terapia , Miastenia Gravis/patología , Humanos , Autoanticuerpos/inmunología , Receptores Colinérgicos/inmunología , Timoma/inmunología , Timoma/patología , Timoma/terapia , Antígenos de Histocompatibilidad Clase I/inmunología , Receptores Fc/inmunología , Proteínas Tirosina Quinasas Receptoras/inmunología , Proteínas Tirosina Quinasas Receptoras/antagonistas & inhibidoresRESUMEN
Thymic epithelial tumors are rare malignancies with an incidence of 1.7 cases per million people per year. They pose significant management challenges due to their association with autoimmune disorders. In this case report, we present the 21-year history of a patient diagnosed with advanced B2/B3 thymoma and Good's syndrome. The patient achieved a complete and durable response after receiving only two cycles of the immune checkpoint inhibitor Nivolumab. However, this positive outcome was accompanied by the development of severe immune-related myocarditis complicated by reactivation of cytomegalovirus. Moreover, the patient developed a highly uncommon subdiaphragmatic pararectal dissemination of the thymic tumor, which is a condition rarely described in the literature. Despite the success in achieving complete and durable response with immune checkpoint inhibitors, the emergence of immune-related adverse events highlights the potential challenges associated with these treatments, emphasizing the need for careful monitoring and a comprehensive understanding of the intricate interplay between cancer, immune system dysregulations and immunotherapy.
Asunto(s)
Inhibidores de Puntos de Control Inmunológico , Neoplasias del Timo , Humanos , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Neoplasias del Timo/inmunología , Neoplasias del Timo/terapia , Neoplasias del Timo/tratamiento farmacológico , Timoma/inmunología , Timoma/terapia , Nivolumab/uso terapéutico , Nivolumab/efectos adversos , Masculino , Inmunoterapia/métodos , Inmunoterapia/efectos adversos , Miocarditis/etiología , Miocarditis/inmunología , Miocarditis/terapia , Miocarditis/tratamiento farmacológico , Resultado del Tratamiento , Persona de Mediana Edad , Neoplasias Glandulares y EpitelialesRESUMEN
Thymoma is closely associated with myasthenia gravis (MG). However, due to the heterogeneity of thymoma and the intricate pathogenesis of MG, it remains unclear why some patients with thymoma develop MG and others do not. In this study, we conducted a comparative phenotype analysis of thymocytes in type B thymomas in patients with MG (MG (+) thymomas) and without MG (MG (-) thymomas) via fluorescence-activated cell sorting (FACS). Our results show that the developmental stages defined by the expression of CD3, CD4, and CD8 were largely maintained in both MG (+) and MG (-) thymomas, with CD4+CD8+ cells constituting the majority of thymocytes in type B thymoma, and no significant difference between this cell population was observed in MG (+) and MG (-) thymomas.We discovered that CD4+CD8+ thymocytes in MG (+) thymomas expressed low levels of αß TCR and high levels of IL-7 receptor α (IL-7Rα), whereas in MG (-) thymomas, CD4+CD8+ thymocytes exhibited the opposite pattern of αß TCR and IL-7Rα expression. These results suggest that the positive and negative selection processes of CD4+CD8+ thymocytes might differ between MG (+) thymomas and MG (-) thymomas. The expression of the Helios transcription factor is induced during negative selection and marks a group of T cells that have undergone negative selection and are likely to be deleted due to strong TCR binding with self-peptides/MHC ligands. We observed that the percentage of Helios-positive CD4SP T cells was greater in MG (-) than in MG (+) thymomas. Thus, the differentially regulated selection process of CD4+CD8+ thymocytes, which involves TCR and IL-7/IL-7Rα signaling, is associated with the presence of MG in type B thymomas.
Asunto(s)
Miastenia Gravis , Receptores de Antígenos de Linfocitos T alfa-beta , Timocitos , Timoma , Humanos , Timoma/inmunología , Timoma/patología , Timoma/metabolismo , Miastenia Gravis/inmunología , Miastenia Gravis/patología , Miastenia Gravis/metabolismo , Receptores de Antígenos de Linfocitos T alfa-beta/metabolismo , Masculino , Timocitos/inmunología , Timocitos/metabolismo , Femenino , Persona de Mediana Edad , Receptores de Interleucina-7/metabolismo , Receptores de Interleucina-7/inmunología , Adulto , Anciano , Neoplasias del Timo/inmunología , Neoplasias del Timo/patología , Neoplasias del Timo/metabolismo , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , InmunofenotipificaciónRESUMEN
Resumo A Síndrome de Good é uma síndrome paraneoplásica caracterizada pela associação de timoma e hipogamaglobulinemia, cursando com imunossupressão. Relatamos um caso raro de retinite por citomegalovírus em paciente com esta síndrome.
Abstract Good syndrome is a paraneoplastic syndrome characterized by the association of thymoma and hypogammaglobulinemia, with immunosuppression. We report a rare case of cytomegalovirus retinitis in a patient with this syndrome.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Timoma/complicaciones , Retinitis por Citomegalovirus/etiología , Agammaglobulinemia/complicaciones , Retina/diagnóstico por imagen , Enfermedades de la Retina/diagnóstico por imagen , Timoma/inmunología , Inmunoglobulina G/sangre , Agudeza Visual , Ganciclovir/administración & dosificación , Ganciclovir/uso terapéutico , Retinitis por Citomegalovirus/diagnóstico , Retinitis por Citomegalovirus/tratamiento farmacológico , Citomegalovirus/inmunología , Agammaglobulinemia/inmunología , Técnicas de Diagnóstico Oftalmológico , Administración IntravenosaRESUMEN
El mediastino anterior es un sitio frecuente de localización de tumores ricos en elementos linfoides. La identificación correcta de cada entidad es de importancia en el tratamiento de los pacientes. En ocasiones puede plantearse el diagnóstico diferencial entre timoma y linfoma linfoblástico con fenotipo de precursor T (LLB-T). La Citometría de Flujo (CF) es una técnica complementaria útil para estos tumores de la cual se obtiene información cualitativa y cuantitativa. Revisamos 38 tumores mediastinales que tenían estudio de CF. Además comparamos los resultados de CF de timomas y tejido tímico normal con 42 casos de LLB-T de otras localizaciones anatómicas. De los 38 tumores mediastinales 6 eran lesiones benignas, 9 linfomas difusos de células grandes con fenotipo B (LDCG-B), 10 linfomas de Hodgkin (LH), 11 timomas y 2 LLB-T. En 24 casos la CF aportó información positiva, definiendo el inmunofenotipo de las células linfoides neoplásicas, o los linfocitos característicos que acompañan a los timomas. La CF en los 10 casos de LH y en 4 lesiones benignas permitió descartar otros tipos de linfoma (LDCG-B, LLB-T, etc.). Las marcaciones para CD3, CD4 y CD8 fueron las más útiles para el diagnóstico diferencial entre timomas y LLB-T. En conclusión, la CF es una técnica complementaria de utilidad que aporta información en lesiones mediastinales de manera rápida, requiriendo cantidades pequeñas de material, tanto para el diagnóstico inicial como para el monitoreo de estas enfermedades.
The anterior mediastinum is a common site of tumors with abundant lymphoid elements. Flow cytometry is a useful complementary technique to analyze this type of tumors, which provides qualitative and quantitative information. A differential diagnosis can be sometimes made between thymoma and precursor T-lymphoblastic lymphoma (T-LBL). Correct identification is of utmost importance for patient treatment. A total of 38 mediastinal tumors were analyzed, and samples were separated for flow cytometry. Flow cytometry data from thymomas and normal thymic tissue were compared with 42 cases of T-LBL from other anatomical locations. Among 38 mediastinal tumors, we found 6 benign lesions, 9 diffuse large B-cell lymphomas (DLBCL), 10 Hodgkin lymphomas (HL), 11 thymomas and 2 T-LL. Flow cytometry provided positive information in 24 cases, and defined lymphoid neoplastic cells immunophenotype or the typical lymphocytes accompanying thymomas. Flow cytometry helped differentiate 10 cases of HL and 4 benign lesions from other lymphomas (DLBCL, T-LBL, etc.). CD3, CD4 and CD8 expressions were most useful for the differential diagnosis of thymomas and T-LL. To conclude, flow cytometry is a valid complementary technique, which promptly provides information on mediastinal lesions, requiring small quantities of tissue for both early diagnosis and follow up of these diseases.
Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Antígenos CD/análisis , Biomarcadores de Tumor , Citometría de Flujo , Neoplasias del Mediastino/patología , Timoma/patología , Neoplasias del Timo/patología , /análisis , /análisis , /análisis , Hiperplasia , Neoplasias del Mediastino/genética , Neoplasias del Mediastino/inmunología , Fenotipo , Estudios Retrospectivos , Linfocitos T/inmunología , Timoma/genética , Timoma/inmunología , Neoplasias del Timo/genética , Neoplasias del Timo/inmunologíaRESUMEN
Las inmunodeficiencias primarias más frecuentes son las humorales, en las que predominan las deficiencias de anticuerpos, y entre éstas las inmunodeficiencias con timoma son raras. En este trabajo se presenta un paciente masculino de 3 años de edad, sin antecedentes familiares de inmunodeficiencia, que a los 21 días de nacido presentó varicela afebril. A partir de un año de edad comenzó a presentar episodios frecuentes de infecciones de vías respiratorias altas (faringoamigdalitis, rinitis purulenta), y bajas como neumonías, o reacciones alérgicas a las picadas de insectos que se infectaban secundariamente. Los estudios inmunológicos revelaron una disminución de las concentraciones séricas de IgG, IgA, (IgG 7.4 g/l, IgA 0.52 g/l), IgM normal (IgM 1g/l) y niveles elevados de IgE (>200u/ml). El estudio radiológico mostró en el mediastino anterior una masa relacionada con el timo. El paciente recibió tratamiento con factor de transferencia, gammaglobulina y se realizó la timectomia por videotoracoscopía. El estudio histológico evidenció un timoma linfocítico benigno. Los linfocitos T CD2+, CD3+, CD8+ estaban disminuidos en el preoperatorio, mientras que en el post operatorio los linfocitos CD2+, CD4+ estaban disminuidos y los CD8+ aumentados
The most frequent primary immunodeficiency is the humoral, where the deficiency of antibodies prevails; among these, the immunodeficiency with thymoma is rare. In this work, a 3- yearold male is presented, without family antecedents of immunodeficiency, which 21 days after birth presented Chicken pox without fever. In the first year of age, he began to present frequent episodes of infections of the upper and the lower respiratory tract: tonsillitis, purulent rhinitis, and pneumonias. He also presented an allergic reaction to insect bites that became infected secondarily. The immunologic studies revealed a decrease of the seric concentrations of IgG, IgA (IgG 7.4 g/l, IgA 0.52 g/l), normal IgM values (IgM 1 g/l) and high levels of IgE (> 200u/ ml). The amount of CD2+, CD3+ and CD8+ T lymphocytes were diminished pre surgery. After surgery, the levels of CD2+, and CD4+ lymphocytes were diminished and those of CD8+ lymphocytes increased. The radiological study showed an anterior, mediastinal mass related to the thymus. The patient received treatment with transfer factor, gammaglobulin and underwent resection of the thymoma for videothoracoscopy. The histology study evidenced a benign lymphocytic thymoma